Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KemPharm And The Curious Case Of Launching A Brand Opioid Like A Generic

Executive Summary

KemPharm is looking to sign a generic drug partner to launch its new brand opioid Apadaz, which says a lot about how the commercial promise of abuse-deterrent opioids has so far failed to materialize. 

Advertisement

Related Content

Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs
Indivior Withdraws 2018 Guidance Due To Competitive Pressures On Suboxone, Sublocade
Abuse-Deterrent Opioids: Where Are They Now?
Egalet's Bid For Arymo ER Intranasal Abuse-Deterrence Claim Blocked By MorphaBond Exclusivity
Can KemPharm's Apadaz Meet FDA Opioid Abuse Deterrent Standards?
KemPharm's Opioid Apadaz Will Likely Miss Out On Abuse Deterrence Claim
The Best Bad Deal of All Time? Pfizer/King and the Business Dynamics of Abuse Deterrence

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel